Forskolin versus Sodium Cromoglycate for Prevention of Asthma Attacks: A Single-blinded Clinical Trial

Servicio de Pediatría, Hospital del Instituto Mexicano del Seguro Social, Manzanillo, Colima, México.
The Journal of international medical research (Impact Factor: 1.44). 03/2006; 34(2):200-7. DOI: 10.1177/147323000603400210
Source: PubMed


To determine the efficacy of forskolin in preventing asthma attacks, we performed a single-blinded clinical study in children and adult out-patients at a public hospital in Mexico. Forty patients of either sex with mild persistent or moderate persistent asthma were assigned randomly to 6 months of treatment with forskolin at 10 mg/day orally (capsules) or with two inhalations of sodium cromoglycate every 8 h, i.e. three times a day. The number of patients who had asthma attacks during the treatment period was significantly lower among those receiving forskolin (8/20, 40%) than among those receiving sodium cromoglycate (17/20, 85%). Values of forced expiratory volume in 1 s and forced expiratory flow, mid-phase, A similar in the two groups during the treatment period. We conclude that forskolin is more effective than sod cromoglycate in preventing asthma attacks in patients with mild persistent or moderate persistent asthma.

Download full-text


Available from: Alejandro Manuel Elizalde, Mar 03, 2014
31 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background: Tight control of intraocular pressure (IOP) is still the only therapeutic approach available for the treatment of primary open angle glaucoma (POAG). However, some patients do not respond adequately to hypotonising drugs, and despite multiple drug combinations they cannot reach their target IOP. Forskolin is a natural compound that has already shown efficacy in IOP reduction following topical application. Purpose: The aim of this study was to evaluate the effects on the IOP of a food supplement containing forskolin and rutin when administered to POAG patients under maximum tolerated medical therapy (MTMT) and on a waiting list for filtrating surgery to further decrease their IOP. Methods: The design of the study was open and case-controlled. Ninety-seven (52 in the treatment group, and 45 in the reference group) patients were enrolled in 8 different glaucoma centers in Italy, all under MTMT and with IOP enrollment values above their target pressure. During the 30 days before surgery, patients in the treatment group were prescribed 2 tablets per day of a food supplement containing rutin and forskolin in addition to their usual topical drug treatment. Their IOP values were measured at 3 time points during the day, at enrollment and once a week until surgery. Control patients continued only with their normal topical therapy. Results: All patients in the treatment group, independently of the combination drug therapy that they were taking, showed a further 10% decrease (P<0.01) of their IOP, starting from 1 week after introduction of the oral supplement and lasting until the last evaluation before surgery. This decrease was more evident (15% of the enrollment value; P<0.01) in those subjects with high (IOP≥21 mmHg) enrollment values rather than in those with low (IOP<21) enrollment values (9%; P<0.01). On the contrary, IOP values in the control group remained stable from the beginning to the end of the observation period, independently of their enrollment values. Conclusions: Forskolin and rutin given as oral treatment appear to contribute to a better control and a further small reduction of IOP in patients who were poorly responsive to multitherapy treatment.
    Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics 06/2012; 28(5):536-41. DOI:10.1089/jop.2012.0021 · 1.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coleus forskohlii Briq. (Family: Lamiaceae) is a fleshy perennial aromatic herb with fibrous roots that grows under tropical to temperate areas in India, Burma, Thailand, Nepal, Pakistan, Sri Lanka, East Africa and Brazil. The rootstock of the plant is used in Ayurveda and other systems of medicine for several ailments such as heart and lung conditions, asthma, digestive disorder, insomnia, muscle spasm, convulsion and skin diseases. Extensive literature survey was performed based on distribution, morphology, phytochemistry and pharmacological aspects of C. forskohlii through pubmed, scopus, SciFinder, google scholar, sciencedirect and ethnobotanical books. Phytopharmacological knowledge and cosmeceutical use of C. forskohlii and its bioactive constituents have been documented. Coleus roots are exclusive source of forskolin, commonly known as fat burning molecule. It’s unique property is activating of almost all hormone sensitive adenylate cyclase enzymes by cyclic 3′,5′-adenosine monophosphate (cAMP). Other potent compounds are 9-deoxyforskolin (1), 1,9-dideoxyforskolin (2), forskolin I (7), forskolin J (8), forskolin L (9), isoforskolin (16), 1-acetylforskolin (17), forskoditerpenoside A (19), forskoditerpenoside B (20), coleol (21), coleosol (22), 3-hydroxyforskolin (25) etc. Besides well established food and traditional use, clinical evidence indicates its safety assessment and can be taken without any toxic effect. This review covers up to date ethnopharmacological, phytochemical and phytomedical information of C. forskohlii approaching towards its safety and therapeutic perspective.
    Oriental Pharmacy and Experimental Medicine 10/2014; 14(4). DOI:10.1007/s13596-014-0169-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since 1971, forskolin has been widely used in research because it activates the ATP pyrophosphate-lyase (cyclizing) enzyme system, EC (adenylate cyclase, AC), resulting in increased cAMP levels. Recently, this terpene has been used as a natural supplement to treat arterial hypertension and asthma through its ability to relax blood vessels. However, animal models have suggested that forskolin may have potential embryotoxicity and teratogenicity in human embryos. Studies show that forskolin is dangerous to the cardiovascular system in developing chick embryos at Hamburger-Hamilton stage 24 (HH24), a stage in which the developing cardiovascular system is modulated by catecholamines. This chapter studies forskolin-induced morphological changes in the cardiovascular system, even when applied in embryos at the HH12 stage, which is characterized by the absence of the catecholaminergic machinery. Eggs containing chick embryos that were incubated for 48 h (HH12-13) were grouped into basal, control and test groups. Embryos were assayed in ovo by injection of 10 µl of forskolin solutions (1.07 x 10-12 mol/egg; 4.14 x 10-12 mol/egg; 8.29 x 10-12 mol/egg; 15.58 x 10-12 mol/egg; 33.16 x 10-12 mol/egg and 66.33 x 10-12 mol/egg) in the air camera of the yolk sac. The basal group did not receive an injection, while the control group was injected with 10 µl of distilled water. No lethality was observed at HH18, when the morphology of the area vasculosa (AV) and the whole embryo was observed. In eggs from the test group, the phenotype of both the AV and the embryo were disrupted depending on the amount of forskolin injected. In contrast, normal cardiovascular development was observed in the AV and in the whole embryos from the basal and control groups. In conclusion, forskolin is potentially toxic for extraembryonic vascular tissues and embryonic cardiovascular system development, even at stages where this system is resistant to catecholamines. These results suggest that forskolin is contraindicated for women who are planning a pregnancy.
    Forskolin: Sources, Mechanisms of Action and Health Effects, 1 edited by Marty H. Walker, 03/2015: chapter 3: pages 51-66; Marty H. Walker., ISBN: 978-1-63463-944-6